Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07169409 · ClinicalTrials.gov registry record · Phase 1

Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings

A Phase 1 study of Opioid Use Disorder, sponsored by Boulder Care.

Recruiting
Registry status
Phase 1
Development phase
250
Enrollment target
1
Study location

NCT07169409 is a Phase 1 study of Opioid Use Disorder that is actively recruiting participants, run by Boulder Care. The registered enrollment target is 250 participants, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07169409, a Phase 1 study of Opioid Use Disorder, is actively recruiting participants, sponsored by Boulder Care.

RECRUITING
Registry status
Phase 1
Development phase
250 participants
Enrollment target
1
Study location

Study Summary

Our primary objective is to evaluate the ability of Boulder Care's telehealth-platform to create the necessary paradigmatic shift in Opioid Use Disorder (OUD) treatment to reach vulnerable populations, with targets that support both equitable and culturally-specific OUD treatment as well as business profitability.

Conditions Studied

Interventions

  • DRUG Telemedicine Buprenorphine Treatment

Study Locations (1)

Oregon

  • Boulder Care - Portland

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2025-06-10
Est. Completion 2027-09-15
Phase Phase 1

Sponsor

Boulder Care

2 total trials

What the Registry Record Tells You About NCT07169409

The ClinicalTrials.gov registry entry for NCT07169409 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (95% lower). The listed sponsor is Boulder Care, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Telemedicine Buprenorphine Treatment is the first listed.

NCT07169409 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT07169409 about?

NCT07169409 is a clinical study titled "Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings". Our primary objective is to evaluate the ability of Boulder Care's telehealth-platform to create the necessary paradigmatic shift in Opioid Use Disorder (OUD) treatment to reach vulnerable populations, with targets that support both equitable and culturally-specific OUD treatment as well as business...

What is the current status of trial NCT07169409?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2025-06-10. Estimated completion is 2027-09-15.

What conditions does trial NCT07169409 study?

This clinical trial studies the following conditions: Opioid Use Disorder.

What interventions are being tested in trial NCT07169409?

The interventions under investigation include: Telemedicine Buprenorphine Treatment (DRUG).

Who is sponsoring clinical trial NCT07169409?

This trial is sponsored by Boulder Care, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07169409 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.